Island Pharmaceuticals Ltd ( (AU:ILA) ) has issued an update.
Island Pharmaceuticals Ltd has completed the Phase 2a/b PROTECT trial for its antiviral drug ISLA-101, aimed at treating dengue fever. The trial’s 2b cohort showed promising results, with the drug achieving target blood level concentrations in all participants, suggesting its potential effectiveness. The company also raised $1.94 million, bolstering its cash reserves to $4.82 million, which supports its ongoing clinical and strategic initiatives. The results of this trial could significantly impact Island Pharmaceuticals’ position in the antiviral drug market and provide value to shareholders.
More about Island Pharmaceuticals Ltd
Island Pharmaceuticals Ltd is an Australian antiviral drug development company focused on creating treatments for viral infections. The company is actively engaged in clinical trials and has a market focus on developing antiviral therapies, particularly for diseases like dengue fever.
YTD Price Performance: -14.71%
Average Trading Volume: 151,808
Technical Sentiment Signal: Sell
Current Market Cap: A$30.49M
See more data about ILA stock on TipRanks’ Stock Analysis page.